In the last trading session, 0.23 million shares of the MBX Biosciences Inc (NASDAQ:MBX) were traded. Most recently the company’s share price was $9.89, and it changed around -$0.65 or -6.17% from the last close, which brings the market valuation of the company to $330.50M. MBX currently trades at a discount to its 52-week high of $27.50, offering almost -178.06% off that amount. The share price’s 52-week low was $9.65, which indicates that the current value has risen by an impressive 2.43% since then. We note from MBX Biosciences Inc’s average daily trading volume that its 10-day average is 0.29 million shares, with the 3-month average coming to 208.78K.

MBX Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended MBX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. MBX Biosciences Inc is expected to report earnings per share of -0.58 for the current quarter.

MBX Biosciences Inc (NASDAQ:MBX) trade information

Instantly MBX has showed a red trend with a performance of -6.17% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 13.41 on recent trading dayincreased the stock’s daily price by 26.25%. The company’s shares are currently down -46.34% year-to-date, but still down -27.76% over the last five days. On the other hand, MBX Biosciences Inc (NASDAQ:MBX) is -48.33% down in the 30-day period. We can see from the shorts that 1.67 million shares have been sold at a short interest cover period of 5.2 day(s).

The consensus price target as assigned by Wall Street analysts is $44, which translates to bulls needing to increase their stock price by 77.52% from its current value. Analyst projections state that MBX is forecast to be at a low of $44 and a high of $44.

MBX Dividends

MBX Biosciences Inc’s next quarterly earnings report is expected to be released in February.

Franklin Strategic Series-Franklin Biotechnology Discove and Driehaus Micro Cap Growth Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 164.5 shares worth $1.63 million, making up 0.49% of all outstanding shares. On the other hand, Driehaus Micro Cap Growth Fund held roughly 96.78 shares worth around $0.96 million, which represents about 0.29% of the total shares outstanding.